Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2011 by University of Pittsburgh.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00343746
First received: June 19, 2006
Last updated: July 25, 2011
Last verified: July 2011
  Purpose

The purpose of this research is to evaluate optical coherence tomography (OCT) and FDA approved device used to image diseases of the eye. The ultra-high resolution OCT is a non-significant risk device used in this study. Optical Coherence Tomography may be useful for early diagnosis and monitoring of different types of eye diseases.


Condition Phase
Macular Degeneration
Glaucoma
Diabetic Retinopathy.
Phase 1

Study Type: Observational
Official Title: Novel Diagnostics With Optical Coherence Tomography: Retinal Imaging

Resource links provided by NLM:


Further study details as provided by University of Pittsburgh:

Estimated Enrollment: 1500
Study Start Date: October 2005
Estimated Study Completion Date: October 2012
Estimated Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Detailed Description:

The purpose of this research is to evaluate optical coherence tomography (OCT) and FDA approved device used to image diseases of the eye. The ultra-high resolution OCT is a non-significant risk device used in this study. OCT may be useful for early diagnosis and monitoring of different types of eye diseases.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Subjects can be 18 to 90 years of age. They can be male or female. Recruiting for normal and diseased subjects.

Criteria

Inclusion Criteria:

  • Subjects with healthy eyes, macular degeneration, glaucoma and other various eye diseases. Also must be able to fixate on target.

Exclusion Criteria:

  • If the fundus is not visible if the media is opaque and if they are unwilling to participate.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00343746

Contacts
Contact: Kristy A Truman 412-383-8778 trumank@upmc.edu
Contact: Melessa Slaay, COA 412-383-9884 salaymd@upmc.edu

Locations
United States, Pennsylvania
University of Pittsburgh UPMC Eye Center Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Principal Investigator: Joel S Schuman, MD         
Sponsors and Collaborators
University of Pittsburgh
Investigators
Study Chair: Joel S Schuman, MD University of Pittsburgh
Principal Investigator: Gadi Wollstein, MD University of Pittsburgh
Study Director: Hiroshi Ishikawa, MD University of Pittsburgh
  More Information

No publications provided

Responsible Party: Gadi Wollstein M.D. / Melessa Salay, UPMC Eye Center
ClinicalTrials.gov Identifier: NCT00343746     History of Changes
Other Study ID Numbers: 0309021, Ro1 EY 11289-15
Study First Received: June 19, 2006
Last Updated: July 25, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by University of Pittsburgh:
macular degeneration
glaucoma
diabetic retinopathy
retinopathy, eye diseases

Additional relevant MeSH terms:
Diabetic Retinopathy
Glaucoma
Macular Degeneration
Retinal Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Diabetic Angiopathies
Endocrine System Diseases
Eye Diseases
Ocular Hypertension
Retinal Degeneration
Vascular Diseases

ClinicalTrials.gov processed this record on November 23, 2014